XML 21 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]      
Revenues $ 1,860.1 $ 1,831.4 $ 1,771.5
Operating expenses:      
Salaries and benefits 550.3 550.0 534.7
Supplies 538.4 507.9 490.3
Professional and medical fees 191.4 154.8 145.5
Lease expense 87.4 85.6 86.7
Other operating expenses 112.8 109.3 104.2
Cost of revenues 1,480.3 1,407.6 1,361.4
General and administrative expenses 97.1 88.6 93.6
Depreciation and amortization 94.8 76.5 67.4
Income from equity investments (10.8) (10.2) (8.9)
Loss (gain) on disposals and deconsolidations, net 5.7 (4.4) 31.8
Transaction and integration costs 23.2 19.0 31.7
Impairment charges 33.5 7.9 74.4
Grant funds (46.2) 0.0 0.0
Loss on debt extinguishment 0.0 11.7 0.0
Litigation settlement 1.2 0.2 46.0
Other income (1.7) (1.4) (3.7)
Total operating expenses 1,677.1 1,595.5 1,693.7
Operating income 183.0 235.9 77.8
Tax receivable agreement expense 0.0 (2.4) 0.0
Interest expense, net (201.8) (178.9) (147.0)
(Loss) income before income taxes (18.8) 54.6 (69.2)
Income tax (benefit) expense (20.1) 9.5 26.4
Net income (loss) 1.3 45.1 (95.6)
Less: Net income attributable to non-controlling interests (117.4) (119.9) (110.1)
Net loss attributable to Surgery Partners, Inc. (116.1) (74.8) (205.7)
Less: Amounts attributable to participating securities (39.5) (35.7) (32.4)
Net loss attributable to common stockholders $ (155.6) $ (110.5) $ (238.1)
Net loss per share attributable to common stockholders - basic and diluted (in USD per share) [1] $ (3.19) $ (2.29) $ (4.96)
Weighted average common shares outstanding - basic and diluted (shares) [1] 48,776 48,280 48,028
[1] The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in those periods.